It’s no secret that the life sciences industry has had some challenging moments with lawmakers in recent years. And despite efforts by the White House, Congress, FDA, and other regulatory agencies, in most cases the law continues to lag behind the industry’s pace of innovation. So, how will the Trump Administration address the industry’s challenges?
Moderator: Senator Norm Coleman – Hogan Lovells
- Jane Axelrad – Axelrad Solutions LLC; Formerly FDA
- Julie Gerberding – Merck & Co., Inc.
- Greg Simon – White House Cancer Moonshot Task Force